Edgar Filing: SAMARITAN PHARMACEUTICALS INC

Ownership Submission

FORM 5

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
	Form 3 Holdings Reported
	Form 4 Transactions Reported

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0362

Expires:

January 31, 2005

Estimated average burden hours per response...

1.0

1. Name and Address of Reporting Person ^*

BOYLE EUGENE

2. Issuer Name and Ticker or Trading Symbol
SAMARITAN PHARMACEUTICALS INC [SPHC]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Chief Financial Officer

(Last)

(First)

(Middle)

101 CONVENTION CENTER DRIVE,Â SUITE 310

3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
12/31/2007

(Street)

LAS VEGAS,Â NVÂ 89109

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Reporting
(check applicable line)
_X_ Form Filed by One Reporting Person
___ Form Filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	Â	Â	Â	Â	Â	Â	53,209	D	Â
Common Stock	Â	Â	Â	Â	Â	Â	95,834	I	By Angels for Emerging Companies Inc.
Common Stock	Â	Â	Â	Â	Â	Â	83,334	I	By Secret Flower, Inc.
Common Stock	Â	Â	Â	Â	Â	Â	2,212,426	I	Samaritan Pharmaceuticals Company Deferred Compensation Plan
Common Stock	Â	Â	Â	Â	Â	Â	18,810	I	By Spouse
Common Stock	Â	Â	Â	Â	Â	Â	83,333	I	Evergreen LifeSciences Inc.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 2270 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Options (right to buy)

$ 3.48

01/15/2003

01/15/2013

Common Stock

215,187

Stock Options (right to buy)

$ 3.48

04/25/2002

04/25/2012

Common Stock

74,154

Stock Options (right to buy)

$ 3.48

01/02/2002

01/02/2012

Common Stock

127,684

Stock Options (right to buy)

$ 3.48

12/31/2001

12/31/2011

Common Stock

127,685

Stock Options (right to buy)

$ 5.76

01/05/2005

01/05/2015

Common Stock

440,182

Stock Options (right to buy)

$ 2.04

01/02/2004

01/02/2014

Common Stock

265,015

Stock Options (right to buy)

$ 3.48

01/02/2004

01/02/2014

Common Stock

89,450

Stock Options (right to buy)

$ 0.49

12/14/2007

12/14/2017

Common Stock

187,500

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
BOYLE EUGENE 101 CONVENTION CENTER DRIVE SUITE 310 LAS VEGAS,Â NVÂ 89109	Â X	Â	Â Chief Financial Officer	Â

Signatures

/s/Eugene Boyle		01/29/2008
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.